SOUTH SAN FRANCISCO, Calif., Nov. 1 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., announced today it will present at the Rodman & Renshaw 8th Annual Healthcare Conference at the Palace Hotel in New York City at 3:30 p.m. Eastern on Monday, November 6, 2006. Paul Sekhri, President and CEO of Cerimon Pharmaceuticals, will provide a company and clinical development overview.
About Cerimon Pharmaceuticals
Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for the physician who specializes in treating autoimmune diseases and inflammation associated with autoimmune diseases. The Company also has an asset in pain management. Cerimon employs a corporate strategy of in-licensing late-stage or marketed drugs to reduce the development and regulatory risk, decrease time to market, and expand the commercial potential of known drugs.
Cerimon currently has two drugs in development, a topical formulation of diclofenac sodium for the treatment of osteoarthritis pain that will enter Phase 3 studies in 2008 and Simulect, which will enter Phase 2b studies for moderate-to-severe steroid-refractory ulcerative colitis early next year. The Company is well financed, having closed a $70 million Series A financing in late 2005 with the premier investors MPM, Nomura Phase 4 Ventures, and OrbiMed Advisors.
For more information on Cerimon, please visit the Company’s Website at http://www.cerimon.com/ .
Cerimon Pharmaceuticals, Inc.
CONTACT: Paul Sekhri, President and CEO of Cerimon Pharmaceuticals, Inc.,+1-650-827-4000; or Juliane Snowden-Andrew, +1-212-213-0006,jsnowden-andrew@burnsmc.com, or Justin Jackson, +1-212-213-0006,jjackson@burnsmc.com, both of Burns McClellan for Cerimon Pharmaceuticals,Inc.
Web site: http://www.cerimon.com/
